Wenxing Yang1, Xuehong Sun2, Jun Zhang2, Kui Zhang3. 1. Department of Physiology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, People's Republic of China. 2. Department of Forensic Pathology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, People's Republic of China. 3. Department of Forensic Pathology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, People's Republic of China. Electronic address: cheungque@163.com.
Abstract
AIM: COVID-19 has spread globally with heavy impact on most countries and our therapeutic strategies in COVID-19 patients with diabetes are still limited. Recently, some new information was added to this field. We performed this updated meta-analysis to reveal the underlying effect of metformin on COVID-19 patients with diabetes. METHODS: We searched the PubMed, Embase and CNKI (China National Knowledge Infrastructure) databases for all articles. The odds ratio (OR) corresponding to the 95% confidence interval (95% CI) was used to assess the effect of metformin on COVID-19 patients with diabetes. The statistical heterogeneity among studies was assessed with the Q-test and I2 statistics. RESULTS: we collected 17 studies including 20,719 COVID-19 patients with diabetes. Our results found that metformin was associated with significantly decreased mortality and severity in COVID-19 patients with diabetes (OR = 0.64, 95% CI = 0.51 - 0.79 for mortality, and OR = 0.81, 95% CI = 0.66 - 0.99 for severity). CONCLUSIONS: our meta-analysis indicated that following metformin treatment might benefit the patients with T2DM, both the mortality and severity. However, patients with severe COVID-19 should be monitored closely for the development of lactic acidosis, acidosis, and decreased kidney function.
AIM: COVID-19 has spread globally with heavy impact on most countries and our therapeutic strategies in COVID-19patients with diabetes are still limited. Recently, some new information was added to this field. We performed this updated meta-analysis to reveal the underlying effect of metformin on COVID-19patients with diabetes. METHODS: We searched the PubMed, Embase and CNKI (China National Knowledge Infrastructure) databases for all articles. The odds ratio (OR) corresponding to the 95% confidence interval (95% CI) was used to assess the effect of metformin on COVID-19patients with diabetes. The statistical heterogeneity among studies was assessed with the Q-test and I2 statistics. RESULTS: we collected 17 studies including 20,719 COVID-19patients with diabetes. Our results found that metformin was associated with significantly decreased mortality and severity in COVID-19patients with diabetes (OR = 0.64, 95% CI = 0.51 - 0.79 for mortality, and OR = 0.81, 95% CI = 0.66 - 0.99 for severity). CONCLUSIONS: our meta-analysis indicated that following metformin treatment might benefit the patients with T2DM, both the mortality and severity. However, patients with severe COVID-19 should be monitored closely for the development of lactic acidosis, acidosis, and decreased kidney function.
Authors: Jaciane Santos-Marques; Marilyse de Oliveira-Meneses; Aline Tavares-Gomes; Elaine Maria Leite Rangel-Andrade; José Ramón Martinez-Riera; Fernando Lopes E Silva-Júnior Journal: Enferm Clin Date: 2022-06-23
Authors: Maria Mercado-Gómez; Endika Prieto-Fernández; Naroa Goikoetxea-Usandizaga; Laura Vila-Vecilla; Mikel Azkargorta; Miren Bravo; Marina Serrano-Maciá; Leire Egia-Mendikute; Rubén Rodríguez-Agudo; Sofia Lachiondo-Ortega; So Young Lee; Alvaro Eguileor Giné; Clàudia Gil-Pitarch; Irene González-Recio; Jorge Simón; Petar Petrov; Ramiro Jover; Luis Alfonso Martínez-Cruz; June Ereño-Orbea; Teresa Cardoso Delgado; Felix Elortza; Jesús Jiménez-Barbero; Ruben Nogueiras; Vincent Prevot; Asis Palazon; María L Martínez-Chantar Journal: Commun Biol Date: 2022-08-17
Authors: Dan Ouchi; Carles Vilaplana-Carnerero; Vanessa de Dios; Maria Giner-Soriano; Rosa Morros Journal: Prim Care Diabetes Date: 2022-10-04 Impact factor: 2.567
Authors: Erin O Wissler Gerdes; Greg Vanichkachorn; Brandon P Verdoorn; Gregory J Hanson; Avni Y Joshi; M Hassan Murad; Stacey A Rizza; Ryan T Hurt; Tamar Tchkonia; James L Kirkland Journal: Transl Res Date: 2021-10-22 Impact factor: 7.012
Authors: Carlos K H Wong; David T W Lui; Angel Y C Lui; Marshall C H Low; Ashley C Y Kwok; Kristy T K Lau; Ivan C H Au; Xi Xiong; Matthew S H Chung; Eric H Y Lau; Benjamin J Cowling Journal: Front Endocrinol (Lausanne) Date: 2022-03-07 Impact factor: 5.555